Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Evaluation of Fisetin to Reduce Systemic Senescence

2 november 2026 uppdaterad av: Steadman Philippon Research Institute

Evaluation of Fisetin to Reduce Systemic Senescence Indices: A Randomized Controlled Dosing Equivalence Study

This is a prospective, randomized clinical trial to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood.

Studieöversikt

Detaljerad beskrivning

This is a prospective, randomized clinical trial designed to examine the effect of two different Fisetin dosing schedules on peripheral blood cells and biomarkers related to aging as well as the occurrence of side effects. The purpose of this study is to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood. 96 healthy volunteers will be randomized into one of two arms (1:1). Group 1 - n= 48: Fisetin Daily Dosing; Group 2 - n=48: Fisetin Bolus Dosing.

Studietyp

Interventionell

Inskrivning (Faktisk)

82

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Colorado
      • Vail, Colorado, Förenta staterna, 81657
        • Steadman Philippon Research Institute

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

55 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Adults ≥55 years of age;
  • Capacity to personally give informed consent (consent via legally authorized representative will not be accepted);
  • Willing to comply with all study procedures and assessments.

Exclusion Criteria:

  • Within 2 years of signing informed consent history of active blood disorders (i.e., DVTs, chronic blood clotting, hemophilia, leukemia, myeloma, etc.); or active malignancy of any type or history of a malignancy (with the exception of Subjects with a history of treated basal or squamous cell carcinoma);

  • Females who are nursing a child, are pregnant, or are planning to become pregnant during drug dosing;

  • Males who do not wish to abstain from sex with women of childbearing potential without use of contraceptive protection by either party during drug dosing;

  • Any significant illness within the last 30 days requiring clinical care, and/or any medications, medical condition, including findings in medical history or in the baseline assessments that, in the opinion of the Principal Clinical Investigator or the screening clinician, constitutes a risk or contraindication for participation in the study or that could interfere with the study conduct, endpoint evaluation, or prevent the subject from fully participating in all aspects of the study;

  • Allergy to any active or inactive ingredient of Fisetin, and/or taking medication with known Fisetin interaction;

  • Subjects with any of the following drug/medication statuses:

    1. Taking medications that affect insulin activity, including Metformin or Acarbose, within one week of signing informed consent;
    2. Currently taking Warfarin or related anticoagulants;
    3. Currently taking Lithium;
    4. Senolytic agents taken within the past 3 months and are not willing to discontinue these medications through the duration of the study, including: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax;
    5. Taking drugs that induce significant cellular stress and are not willing to discontinue these medications through the duration of the study, including alkylating agents, anthracyclines, platins, and other chemotherapy drugs;
    6. Taking the following drugs if they cannot be held (per the Principal Investigator) for at least 2 days before and during administration of Fisetin: cyclosporine, tacrolimus, repaglinide, and bosentan;
    7. Taking a glucocorticoid within 1 month of signing informed consent;
    8. Currently taking phenytoin or nateglinide;
  • PHQ-9 - Patient Health Questionnaire - total score exceeds 9;

  • Inability to tolerate oral medication;

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Fisetin (daily dosing)

A single Fisetin 100mg capsule will be taken daily for 60 days.

Oral Fisetin 100mg capsule

Andra namn:
  • 3,3',4',7-tetrahydroxiflavon
  • Novusetin
  • 7,3',4'-flavon-3-ol
Experimentell: Fisetin (bolus dosing)

Fisetin 100 mg capsules (~20 mg/ kg/ day) will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. This cycle of 2 dosing days followed by 28 days off will repeat for a total of 2 cycles, or 4 dosing days total. Dosing days will occur on days 1&2, and 31&32.

Oral Fisetin 100mg capsule, dosed at 20 mg/kg

Andra namn:
  • 3,3',4',7-tetrahydroxiflavon
  • Novusetin
  • 7,3',4'-flavon-3-ol

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)
Tidsram: Baseline, Visit 4 (45 days)

Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels.

Baseline, Visit 4 (45 days)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)
Tidsram: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 5 (60 days)

Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels.

Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 5 (60 days)
Change from baseline in senescence-related serum biomarkers
Tidsram: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)

Concentrations of proteins related to senescence will be analyzed using multiplex immunoassays and ELISA from serum/plasma.

Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
Number of participants experiencing one or more treatment-emergent adverse events
Tidsram: From date of study drug dosing until the end of the study, an average of 2 months

Number of participants experiencing one or more treatment-emergent adverse events

From date of study drug dosing until the end of the study, an average of 2 months
Perturbations in senescent PBMC values
Tidsram: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)

Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels.

Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
Perturbations in senescent serum/plasma biomarkers values
Tidsram: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)

The variability over visits of serum/plasma concentrations of proteins related to senescence will be assessed using multiplex immunoassay and ELISA.

Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Johnny Huard, PhD, Steadman Philippon Research Institute

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

24 maj 2023

Primärt slutförande (Faktisk)

30 januari 2024

Avslutad studie (Faktisk)

30 januari 2024

Studieregistreringsdatum

Först inskickad

21 oktober 2026

Först inskickad som uppfyllde QC-kriterierna

2 november 2026

Första postat (Faktisk)

5 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • 2022-154

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera